Sign In
|
Register
|
About San Anselmo
|
Contact Us
San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast
|
Traffic
San Anselmo News
Local News
Bay Area News
Business
Technology
Real Estate
Sports
High School Sports
San Anselmo Gas Prices
Ski And Snow Reports
Financial Markets
Bakery
Brew Pubs
Coffee Houses
Eating Places
Fast Food
Seafood
Sports Bars
Steaks, Chops
Wine
Bars and Lounges
Dinner & Music Theatres
Events & Concerts
Live Music
Night Clubs
Attractions
Antiques
Nightlife
Family Activities
Arts & Culture
Annual Events
Accommodations
Hotel and Motel Management
Hotels & Resorts
Apartments
Apartment Finding & Rentals
Apartments
Senior Apartments
Art & Culture
Galleries & Dealers
Museums
Theatres
Associations, Foundations and Organizations
Business & Professional Clubs
Chambers of Commerce
Civic, Social and Fraternal
Non-Profits
Professional & Trade Associations
Sales Organizations
Attractions & Entertainment
Amusement & Water Parks
Galleries
General Attractions
Museums
Parks & Preserves
Theatre
Automotive
Dealers - Antique & Classic
Dealers - New
Dealers - Used
Motorcycles
Parts & Supplies
Repair & Service
Beauty & Fitness
Barbers
Beauty Salons
Dance Clubs & Studios
Fitness Programs
Health Clubs & Gyms
Massage
Business & Professional Services
Appraisers
Building Maintenance & Janitorial
Business Legal Services
Communications Services
Computer & Audio Visual Services
Consultants
Copier & Fax Services, Equipment
Data Processing Service
Durable Goods
Employment Services, Placement & Agencies
Engineer and Architect Services
Equipment & Supplies, Commercial & Industrial
Graphic Design & Art
Human Resource Services
Management Services
Marketing & Advertising Services
Media Services
Office Furniture, Equipment & Supplies
Photography
Printing & Publishing
Public Relations & Publicity
Research
Security & Investigative Services
Shipping, Packaging & Postal Services
Signs & Banners
Staffing & Support Services
Telecommunications
Trucking & Hauling
Video Production
Commercial Contractors
Concierge & Lifestyle Services
Contractors
Architects
Building Contractors & Consultants
Electric
General Contractors
Heating, Cooling & AC
Landscaping
Painting & Wallcovering
Plumbing
Special Trade Contractors
Domestic Services
Child Care Services
Pet Sitting and Day Care
Education
Art Education
Colleges & Universities
Cont. Education
Elementary Schools
High Schools
Libraries
Middle Schools
Preschools & Childcare
Private & Parochial
Public
Tutoring
Employment
Employment Agencies
Find or Post a Job
Temporary Help & Employment Contractors
Financial Services
Accountants & Tax
Appraisers
Banks & Credit Unions
Bookkeeping
Financial Brokers and Dealers
Financial Consultants
Financial Planning and Services
Investments
Loans
Misc. Financial Services
Mortgage Lenders
Personal
Government
Post Offices
Health and Medicine
Alternative Medicine / Acupuncture
Animal Health
Chiropractors
Counseling
Dentistry
Drug Stores & Pharmacies
Eye Care
Health Care Professionals
Home Health Care
Hospitals & Clinics
Massage
Medical Doctors
Mental Health
Physical Therapist
Physicians & Surgeons
Social Services
Specialists - Health Care Professionals
Home & Garden
Accessories
Bed & Bath
Cabinets, Racks & Shelves
Carpets & Rugs
Cleaning Supplies & Services
Contractors
Electric
Floor Coverings
Furniture
Heating, Cooling & AC
Home Improvement Centers
Kitchen
Lamps & Lighting
Lawn & Garden
Masonry & Stone Work
Nurseries & Garden Centers
Painting & Wallcoverings
Plumbing
Tree Services
Insurance
Agents & Brokers
Auto
Health
Home
Life
Pets
Legal
Attorneys
Legal Services
Manufacturing & Industrial
Agriculture
Food & Beverage
Media
Cable & Pay TV Services
Print Publications
Television Stations
Meeting & Event Planning
Audio & Visual
Event Facilities
Exhibit Designers
Lodging
Meeting Planners
Party Rentals & Entertainment
Travel Arrangement & Services
Miscellaneous
Nightlife
Bars and Lounges
Dinner & Music Theatres
Events & Concerts
Live Music
Night Clubs
Personal Service
Barbers, Beauty Salons & Spas
Shoe Repair
Pets
Pet Shops
Training
Veterinary Hospitals
Real Estate
Appraisers
Commercial
Condominiums
Developers
Mortgage Lenders
Property Management
Real Estate Agents and Brokers
Residential
Religion
Relocation
Movers
Storage
Restaurants
Bakery
Brew Pubs
Coffee Houses
Eating Places
Fast Food
Seafood
Sports Bars
Steaks, Chops
Wine
Shopping
Accessories
Antiques
Books
Bridal Shops
Cellular & Wireless
Children's and Infants Clothing
Clothing
Computer and Computer Software
Convenience Stores
Department Stores
Discount Stores
Flowers
Furniture
Gas Stations
Gifts & Specialty Shops
Gourmet & Specialty Foods
Grocery Stores
Health Food Stores
Home Improvement
Indian Arts & Crafts - Retail
Jewelry
Men's Clothing Stores
Notions
Office Supplies & Service
Pharmacies
Repair Shops
Resale Shops
Shoe Stores
Sporting Goods
Thrift Stores
Videos
Women's Clothing Stores
Spas
Beauty Salons
Sports & Recreation
Bicycles
Dance Clubs & Studios, Instruction
Health Clubs
Instruction
Recreation Facilities
Sporting Goods
Technology
Communications
Computer Maintenance and Repair
Computer Services & Consultants
E-commerce
Internet Advertising & Services
Semiconductor
Software
Web Design
Web Development
Travel & Transportation
Hotels & Resorts
Taxi, Limousine & Shuttle
Travel Agencies
Weddings
Bridal Shops
Entertainment
Florists
Health & Beauty
Photographers & Videographers
Apartments
Classifieds
Cars
Forums
Coupons
News Archives
Contests
Jobs
Search Hotels in San Anselmo
CHECK-IN:
CHECK-OUT:
ROOMS:
1
2
3
4
Find A Business
or
Browse Listings
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
66.78
-1.27 (-1.87%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Astrazeneca Plc ADR
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer
October 21, 2023
From
AstraZeneca
Via
Business Wire
TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline
October 21, 2023
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone
October 20, 2023
From
AstraZeneca
Via
Business Wire
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
October 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer
October 16, 2023
From
AstraZeneca
Via
Business Wire
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
October 13, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge
October 12, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO
October 11, 2023
From
AstraZeneca
Via
Business Wire
Astrazeneca Foundation Awards 12 Nonprofit Organizations More Than $2M to Advance Health Equity
October 10, 2023
From
AstraZeneca Foundation
Via
Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
September 22, 2023
From
AstraZeneca
Via
Business Wire
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
September 20, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress...
Via
FinancialNewsMedia
AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment
September 14, 2023
From
AstraZeneca
Via
Business Wire
FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)
September 11, 2023
From
AstraZeneca
Via
Business Wire
TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial
September 11, 2023
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial
September 11, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients
August 25, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030
August 16, 2023
From
AstraZeneca
Via
Business Wire
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential
August 04, 2023
Via
Investor Brand Network
Exposures
Product Safety
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
July 27, 2023
From
AstraZeneca
Via
Business Wire
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
July 03, 2023
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial
June 29, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
June 28, 2023
From
AstraZeneca
Via
Business Wire
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
June 26, 2023
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t
Via
MarketBeat
AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites
June 13, 2023
From
AstraZeneca
Via
Business Wire
Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer
June 12, 2023
From
AstraZeneca
Via
Business Wire
Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
June 05, 2023
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors
June 05, 2023
From
AstraZeneca
Via
Business Wire
ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care
June 05, 2023
From
AstraZeneca
Via
Business Wire
TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
June 04, 2023
From
AstraZeneca
Via
Business Wire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
About Us
|
Contact Us
|
Privacy Policy
|
User Agreement
|
Advertise With Us
|
Site Map
San Anselmo
|
San Anselmo News
|
San Anselmo Travel
|
Restaurants
|
Nightlife
|
Things To Do
|
Shopping
|
Calendar
|
Directory
|
Real Estate
|
Blog
|
More
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.